Modernizing clearance and quantification of host-cell proteins in mAb manufacture

To Improve reliability and quality assurance of the manufacturing processes through purification of monoclonal antibodies(mAbs) made by Chinese Hamster Ovary(CHO)
Categories
Process control
Active Immunization Countermeasures

Industry Need

  • Host-cell proteins (HCPs) are a major class of impurities in biopharmaceutical manufacturing. 
  • The removal of HCPs is complicated by the need to reduce both the total HCP content and the amounts of individual species that can be harmful to the product and/or patients.

Approach

Led by the University of Delaware, the team will develop new and complementary technologies for achieving and monitoring the removal of host-cell proteins (HCPs) in purification of monoclonal antibodies (mAbs) made by Chinese hamster ovary (CHO) cells.

Impacts

HCP removal in multiple applications by employing novel LigaGuardTM materials that specifically capture CHO HCPs.

Benchmark and standardize liquid chromatography-mass spectrometry (LC-MS) technology to monitor HCP levels in biomanufacturing

characterize HCP aggregates that contribute to HCP persistence in process streams and hence develop new methods to improve their removal.

This will be accomplished by improving HCP removal in multiple applications by employing novel LigaGuardTM materials that specifically capture CHO HCPs while allowing the mAb product to flow through unbound, characterizing HCP aggregates that contribute to HCP persistence in process streams and develop new methods to improve their removal, and benchmarking and standardizing liquid chromatography-mass spectrometry (LC-MS) technology to monitor HCP levels in biomanufacturing.

Outputs/Deliverables

Coming soon

Posters

Lenhoff, A., Conference Participant, 5.2-133: Modernizing Clearance and Quantification of Host-Cell Proteins in mAb Manufacture, NIIMBL National Meeting, Washington, D.C., June 26, 2025.

Presentations

Lenhoff, A., Understanding and Mitigating Persistence of CHO Host-Cell Proteins in MAb Bioprocessing, ISPPP 2023 (Intl. Symposium on Separations of Proteins, Peptides and Polynucleotides, Vienna, Austria, November 7, 2023.

Menegatti, S., Mouchahoir, T., Lenhoff, A., Cramer, S., Bill, J., Li, S. X., Xu, X., Tully, T., & Crapanzano, M., Modernizing Clearance and Quantification of Host-Cell Proteins in mAb Manufacture, NIIMBL National Meeting, Washington, DC, June 27, 2024.

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

University of Delaware

University of Delaware

Participating Organizations

Bristol-Myers Squibb

Bristol-Myers Squibb

Chromagenix

Chromagenix

Federal Stakeholder:  National Institute of Standards and Technology

Federal Stakeholder: National Institute of Standards and Technology

Genentech, Inc.

Genentech, Inc.

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

North Carolina State University

North Carolina State University

Pfizer, Inc.

Pfizer, Inc.

Rensselaer Polytechnic Institute

Rensselaer Polytechnic Institute